Top

BMC Women's Health

Published in:

Open Access 01-12-2017 | Research article

Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis

Authors: Ning Tang, Dan Lyu, Yan Zhang, Haiping Liu

Published in: BMC Women's Health | Issue 1/2017

Abstract

Background

Ovarian cancer is a prominent public health problem which affects people all around the world. Platinum-based chemotherapy is a common treatment for ovarian cancer, however, the effectiveness of chemotherapy varies from patient to patient. The excision repair cross complementation group 1 (ERCC1) protein may mediate chemotherapy resistance. A meta-analysis was conducted to explore whether platinum-based chemotherapy effectiveness could be attributed to the ERCC1 C19007T polymorphisms.

Methods

Seven major databases (EMBASE, Web of Science, Pubmed, Springer Link, Chinese National Knowledge Infrastructure (CNKI), EBSCO and Science Direct databases) were searched for eligible studies. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the results.

Results

In this meta-analysis, 1169 subjects (425 non-responders and 744 responders) from 8 studies were included. The overall OR (C vs. T alleles) using random model was 1.07 (95% CI 0.75-1.52, P = 0.7), which was not statistically significant. Moreover, there was no significant difference in the analysis by race.

Conclusion

There is no association between the ERCC1 C19007T polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer. The polymorphism did not have a significant impact on platinum-based chemotherapy in non-responders and responders.

(WHO) WHO: Global cancer rates could increase by 50% to 15 million by 2020. 2003.

Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mut Res/Mutation Res Genomics. 1997;382(1–2):13–20.

Yan L, Pei H, Yu C, Gui-ying W, Na W, Rong-miao Z. Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/a polymorphism of ERCC1: a meta-analysis. Biomarkers. 2014;19(2):128–34.CrossRef

Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev. 2007;33(6):565–77.CrossRefPubMed

Reed E, Larkins TL, Chau CH, Figg WD. DNA Repair: ERCC1. Nucleotide Excision Repair Platinum Resistance. 2014:333–49.

Deloia JA, Bhagwat NR, Darcy KM, Strange M, Tian C, Nuttall K, et al. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. Gynecol Oncol. 2012;126(3):448–54.

Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, et al. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic oncology group study. Gynecol Oncol. 2012;125(2):421–6.CrossRefPubMedPubMedCentral

Koc E, Caner V, Buyukpinarbasili N, Tepeli E, Turk NS, Ozan Cetin G, et al. The determination of relationship between "excision repair cross-complementing group 1" (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer. Mol Biol Rep. 2012;39(1):375–80.

De Castro G Jr, Pasini FS, Siqueira SA, Ferraz AR, Villar RC, Snitcovsky IM, et al. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep. 2011;25(3):693–9.

10.

Moxley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, et al. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecol Oncol. 2013;130(2):377–82.CrossRefPubMed

11.

Qi BL, Li Y, Wang N, Zhou RM, Hu P, Kang S. Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy. Zhonghua Fu Chan Ke Za Zhi. 2013;48(11):847–52.PubMed

12.

Bagos PG. Genetic model selection in genome-wide association studies: robust methods and the use of meta-analysis. Stat Appl Genet Mol Biol. 2013;12(3):285–308.CrossRefPubMed

13.

Begg CB, Berlin JA. Publication bias and dissemination of clinical research. J Natl Cancer Inst. 1989;81(2):107–15.CrossRefPubMed

14.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.CrossRefPubMedPubMedCentral

15.

Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443–57.CrossRefPubMed

16.

Smith S, Su D, Rigault De La Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol. 2007;25(33):5172–9.

17.

Steffensen KD, Waldstrom M, Jeppesen U, Brandslund I, Jakobsen A. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer. 2008;18(4):702–10.CrossRefPubMed

18.

Kang S, Woong J, Kim JW, Park N-H, Song Y-S, Kim SC, et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Gynecol Oncol. 2009;38(3):320–4.

19.

Bösmüller H, Haitchi-Petnehazy S, Webersinke G, Marschon R, Roithmeier F, Stummvoll W, et al. Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy. Virchows Arch. 2011;459(2):183–91.CrossRefPubMed

20.

Steffensen KD, Waldstrøm M, Jakobsen A. DNA-repair ERCC1 Gene polymorphisms in epithelial ovarian cancer and relation to platinum resistance and survival. J Cancer Ther. 2011;2(2):140–7.CrossRef

21.

Shuying Y. ERCC1 gene polymorphisms and ovarian epithelial carcinoma patients with platinum chemotherapy sensitivity and prognostic relationship. Master degree. Shijiazhuang: Hebei medicine university; 2011.

22.

Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. Shijiazhuang: J Epidemiol. 2005;15(6):235–43.

23.

Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol. 2000;16(3):555–60.

24.

Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, Patrick SM. Downregulation of XPF–ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair. 2010;9(7):745–53.CrossRefPubMedPubMedCentral

25.

Liccardi G, Hartley JA, Hochhauser D. Importance of EGFR/ERCC1 interaction following radiation-induced DNA damage. Clin Cancer Res. 2014;20(13):3496–506.CrossRefPubMed

26.

Allione A, Guarrera S, Russo A, Ricceri F, Purohit R, Pagnani A, et al. Inter-individual variation in nucleotide excision repair pathway is modulated by non-synonymous polymorphisms in ERCC4 and MBD4 genes. Mutat Res. 2013;751–752:49–54.CrossRefPubMed

27.

Slyskova J, Lorenzo Y, Karlsen A, Carlsen MH, Novosadova V, Blomhoff R, et al. Both genetic and dietary factors underlie individual differences in DNA damage levels and DNA repair capacity. DNA Repair (Amst). 2014;16:66–73.

28.

Vilmar A, Sørensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009;64(2):131–9.CrossRefPubMed

29.

Vooder T, Metspalu A. Investigating gene expression profile of non-small cell lung cancer. Central European Journal of Medicine. 2011;6(5):608–15.

30.

Masters JR, Koberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer. 2003;3(7):517–25.CrossRefPubMed

31.

Liu L, Li CH, Jin TF, Xu DY. Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer. Genet Mol Res. 2014;13(4):8722–8.CrossRefPubMed

32.

Tsodikov OV, Enzlin JH, Scharer OD, Ellenberger T. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1. Proc Natl Acad Sci U S A. 2005;102(32):11236–41.CrossRefPubMedPubMedCentral

Title: Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
Authors: Ning Tang
Dan Lyu
Yan Zhang
Haiping Liu
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Women's Health / Issue 1/2017
Electronic ISSN: 1472-6874
DOI: https://doi.org/10.1186/s12905-017-0393-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

Cardiovascular RiskprofilE - IMaging and gender-specific disOrders (CREw-IMAGO): rationale and design of a multicenter cohort study

Treatment delays among women with breast cancer in a low socio-economic status region in Brazil

Sex hormone binding globulin as a valuable biochemical marker in predicting gestational diabetes mellitus

Clinicopathologic and prognostic features of breast cancer in young women: a series from North of Morocco

Aggressive behaviour among drug-using women from Cape Town, South Africa: ethnicity, heavy alcohol use, methamphetamine and intimate partner violence

Results of a pilot study in the U.S. and Vietnam to assess the utility and acceptability of a multi-level pregnancy test (MLPT) for home monitoring of hCG trends after assisted reproduction